MX2012009976A - Uretanos, ureas, amidinas e inhibidores relacionados del factor xa. - Google Patents
Uretanos, ureas, amidinas e inhibidores relacionados del factor xa.Info
- Publication number
- MX2012009976A MX2012009976A MX2012009976A MX2012009976A MX2012009976A MX 2012009976 A MX2012009976 A MX 2012009976A MX 2012009976 A MX2012009976 A MX 2012009976A MX 2012009976 A MX2012009976 A MX 2012009976A MX 2012009976 A MX2012009976 A MX 2012009976A
- Authority
- MX
- Mexico
- Prior art keywords
- factor
- compounds
- pharmaceutically acceptable
- amidines
- urethanes
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 2
- 150000001409 amidines Chemical class 0.000 title 1
- 235000013877 carbamide Nutrition 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 150000003673 urethanes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 206010014498 Embolic stroke Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010043647 Thrombotic Stroke Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 238000007887 coronary angioplasty Methods 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención se refiere a una nueva clase de compuestos, sus sales farmacéuticamente aceptables y composiciones farmacéuticamente aceptables que son efectivos como inhibidores selectivos del factor Xa, tanto en el estado aislado como en complejo con otras proteínas. Los compuestos de la invención pueden utilizarse para tratar y prevenir enfermedades, tales como el síndrome coronario agudo, infarto al miocardio, angina inestable, angina refractaria, trombosis causada por terapia post-trombolítica o angioplastia coronaria, síndrome cerebrovascular mediado por isquemia aguda, accidente cerebrovascular embólico, accidente cerebrovascular trombótico y otras enfermedades en humanos y otros mamíferos, asociadas con problemas de coagulación sanguínea.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201000506A EA015918B1 (ru) | 2010-03-03 | 2010-03-03 | УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa |
| PCT/RU2011/000129 WO2011108963A1 (en) | 2010-03-03 | 2011-03-02 | Urethanes, ureas, amidines and related inhibitors of factor xa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012009976A true MX2012009976A (es) | 2012-12-17 |
Family
ID=44542428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009976A MX2012009976A (es) | 2010-03-03 | 2011-03-02 | Uretanos, ureas, amidinas e inhibidores relacionados del factor xa. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9708265B2 (es) |
| EP (1) | EP2542529B1 (es) |
| JP (1) | JP6078707B2 (es) |
| KR (1) | KR101771760B1 (es) |
| CN (1) | CN102971294B (es) |
| AU (1) | AU2011221601B2 (es) |
| BR (1) | BR112012021884B8 (es) |
| CA (1) | CA2791875C (es) |
| CY (1) | CY1122645T1 (es) |
| DK (1) | DK2542529T3 (es) |
| EA (1) | EA015918B1 (es) |
| HR (1) | HRP20192125T1 (es) |
| HU (1) | HUE047249T2 (es) |
| IL (1) | IL221727A (es) |
| LT (1) | LT2542529T (es) |
| MX (1) | MX2012009976A (es) |
| NZ (1) | NZ602769A (es) |
| PL (1) | PL2542529T3 (es) |
| PT (1) | PT2542529T (es) |
| SI (1) | SI2542529T1 (es) |
| UA (1) | UA107106C2 (es) |
| WO (1) | WO2011108963A1 (es) |
| ZA (1) | ZA201207345B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014003153A1 (ja) * | 2012-06-28 | 2014-01-03 | 協和発酵キリン株式会社 | 置換アミド化合物 |
| RU2698202C2 (ru) * | 2016-06-01 | 2019-08-23 | Закрытое акционерное общество "ФАРМА ВАМ" | СПОСОБ ПОЛУЧЕНИЯ ПРЯМОГО ИНГИБИТОРА ФАКТОРА Ха |
| EA030138B1 (ru) * | 2016-06-15 | 2018-06-29 | Общество С Ограниченной Ответственностью "Фармадиол" | Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид |
| RU2659161C1 (ru) | 2017-11-17 | 2018-06-28 | Общество С Ограниченной Ответственностью "Ива Фарм" | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид |
| EA032764B1 (ru) * | 2018-01-19 | 2019-07-31 | Общество С Ограниченной Ответственностью "Фармадиол" | НОВЫЕ АМИДИНЫ - ИНГИБИТОРЫ ФАКТОРА Xa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588587A (en) | 1983-03-01 | 1986-05-13 | Pennsylvania Hospital | Method of treatment to inhibit metastasis |
| DE69529770T2 (de) | 1994-12-02 | 2003-12-24 | Yamanouchi Pharmaceutical Co., Ltd. | Neues amidinonaphthylderivat oder dessen salz |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| HUP0000735A3 (en) | 1996-12-23 | 2002-03-28 | Bristol Myers Squibb Pharma Co | Nitrogen containing heteroaromatics as factor xa inhibitors |
| KR20010023364A (ko) | 1997-08-27 | 2001-03-26 | 간자와 무츠와 | 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체 |
| JP4744050B2 (ja) * | 1999-09-17 | 2011-08-10 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ベンズアミドおよび関連するＸａ因子阻害剤 |
| AU2108601A (en) * | 1999-12-15 | 2001-06-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US6376515B2 (en) * | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| AU2002350217A1 (en) * | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| DE102005042583A1 (de) * | 2005-09-08 | 2007-03-15 | Bayer Healthcare Ag | Iminooxazolidin-Derivate und ihre Verwendung |
| CN102336702B (zh) * | 2005-11-08 | 2015-02-11 | 米伦纽姆医药公司 | Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型 |
| EP2101760B1 (en) * | 2006-12-08 | 2013-02-27 | Millennium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
-
2010
- 2010-03-03 EA EA201000506A patent/EA015918B1/ru unknown
-
2011
- 2011-02-03 UA UAA201211358A patent/UA107106C2/ru unknown
- 2011-03-02 PL PL11750982T patent/PL2542529T3/pl unknown
- 2011-03-02 PT PT117509828T patent/PT2542529T/pt unknown
- 2011-03-02 KR KR1020127025881A patent/KR101771760B1/ko active Active
- 2011-03-02 JP JP2012556036A patent/JP6078707B2/ja active Active
- 2011-03-02 CN CN201180011928.4A patent/CN102971294B/zh active Active
- 2011-03-02 CA CA2791875A patent/CA2791875C/en active Active
- 2011-03-02 LT LT11750982T patent/LT2542529T/lt unknown
- 2011-03-02 HR HRP20192125TT patent/HRP20192125T1/hr unknown
- 2011-03-02 MX MX2012009976A patent/MX2012009976A/es active IP Right Grant
- 2011-03-02 EP EP11750982.8A patent/EP2542529B1/en active Active
- 2011-03-02 WO PCT/RU2011/000129 patent/WO2011108963A1/en not_active Ceased
- 2011-03-02 AU AU2011221601A patent/AU2011221601B2/en active Active
- 2011-03-02 HU HUE11750982A patent/HUE047249T2/hu unknown
- 2011-03-02 NZ NZ602769A patent/NZ602769A/en unknown
- 2011-03-02 BR BR112012021884A patent/BR112012021884B8/pt not_active IP Right Cessation
- 2011-03-02 DK DK11750982.8T patent/DK2542529T3/da active
- 2011-03-02 SI SI201131816T patent/SI2542529T1/sl unknown
-
2012
- 2012-08-30 US US13/599,038 patent/US9708265B2/en active Active
- 2012-08-30 IL IL221727A patent/IL221727A/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07345A patent/ZA201207345B/en unknown
-
2019
- 2019-10-03 CY CY20191101032T patent/CY1122645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6551666A2 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
| CL2014000925A1 (es) | Compuestos derivados de tetrahidroisoquinolina sustituidos, inhibidores del factor de coagulacion xia (fxia); composicion farmaceutica que los comprende; y su uso para el tratamiento de un trastorno tromboembolico o inflamatorio seleccionado de angina inestable, sindrome coronario agudo y fibrilacion atrial, entre otros. | |
| MX361759B (es) | Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico. | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| CY1122645T1 (el) | Oyρεθανες, ουριες, αμιδινες και σχετικοι αναστολεις του παραγοντα χα | |
| EA201790595A1 (ru) | Пиримидиноны в качестве ингибиторов фактора xia | |
| EA201400729A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| PH12014500137A1 (en) | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| NZ729600A (en) | Binding proteins specific for lox1 and uses thereof | |
| ECSP11011483A (es) | Piperidinas sustituidas | |
| CL2007002067A1 (es) | Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras. | |
| CU20110214A7 (es) | Piperidinas sustituidas | |
| CL2007001091A1 (es) | Compuestos derivados de ciclopropan dicarboxamida, inhibidores del factor de coagulacion xa; composiciones farmaceuticas; y su uso para tratar desordenes tromboticos, trombosis arterial o venosa, trombosis venosa profunda, enfermedad arterial periferica oclusiva y angina pectoris inestable, infarto al miocardio, entre otras. | |
| DOP2013000182A (es) | Inhibidores de catepsina c | |
| CL2011002967A1 (es) | Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales. | |
| CO6612187A2 (es) | Inhibidores de catepsina c | |
| EA201800084A1 (ru) | НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха | |
| TN2011000588A1 (en) | Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses | |
| CL2009001927A1 (es) | Compuestos derivados de 4-(2-oxo-1,2-dihidro-4-piridinil)-3-piperidina carboxamida; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hipertension, insuficiencia cardiaca congestiva, hipertension pulmonar, aterosclerosis, entre otras. | |
| CR20120103A (es) | Inhibidores de catepsina c | |
| CL2007003039A1 (es) | Compuestos derivados de heteroaril-carboxamida, inhibidores del factor de coagulacion xa; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como trombosis, angina de pecho e infarto al miocar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |